ClinicalTrials.Veeva

Menu

CPG 7909 Injection in Melanoma

Pfizer logo

Pfizer

Status and phase

Completed
Phase 2

Conditions

Carcinoma, Melanoma

Treatments

Drug: CPG 7909 Injection
Drug: dacarbazine
Drug: Chemotherapy

Study type

Interventional

Funder types

Industry

Identifiers

NCT00070642
C023
CO23, A8501023

Details and patient eligibility

About

To determine the safety, tolerability and effects of CPG 7909 (the study drug) when given with chemotherapy to patients with melanoma.

Enrollment

184 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histologically or cytologically confirmed melanoma that is metastatic.
  • Measurable disease according to the RECIST criteria.
  • Karnofsky Performance Status of > 70.

Exclusion criteria

  • Prior treatment with anti-neoplastic biologic or chemotherapy for recurrent or metastatic disease (except one course of adjuvant immunotherapy and/or adjuvant chemotherapy other than DTIC).
  • Suspected or known CNS metastases.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

184 participants in 4 patient groups

CPG 7909 Injection plus chemotherapy
Experimental group
Description:
CPG 7909 Injection plus DTIC
Treatment:
Drug: CPG 7909 Injection
Drug: dacarbazine
Drug: CPG 7909 Injection
Drug: CPG 7909 Injection
Chemotherapy alone
Active Comparator group
Description:
dacarbazine
Treatment:
Drug: Chemotherapy
CPG 7909 Injection 10 mg
Experimental group
Treatment:
Drug: CPG 7909 Injection
Drug: CPG 7909 Injection
Drug: CPG 7909 Injection
CPG 7909 Injection 40 mg
Experimental group
Treatment:
Drug: CPG 7909 Injection
Drug: CPG 7909 Injection
Drug: CPG 7909 Injection

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems